<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-150366</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment of gait disorders in Parkinson's disease</dc:title>
<dc:description xml:lang="en">There is currently a growing interest in the study of the extra-nigral symptoms of Parkinson's disease, such as gait disorders, which result in an important reduction in quality of life. Walking is a complex process and the problems affecting it can be explained by the sum of elements like hypokinesia, asymmetry in the movement of the two halves of the body, executive dysfunction, alterations affecting proprioceptive sensitivity, and environmental and emotional factors. The activation of a number of different brain structures and neurotransmitters involved in the regulation of gait and posture is altered in Parkinson's disease. In the early phases gait disorders are controlled to an acceptable extent with dopaminergic drugs, but the response to these agents is not satisfactory in advanced phases. This has led researchers to look for substances with other mechanisms of action (methylphenidate, dihydroxyphenylserine, anticholinesterases, memantine and selective serotonin receptor inhibitors, among others) and non-pharmacological treatments such as surgery (deep brain stimulation of the subthalamic nucleus and of the pedunculopontine), physiotherapy and acupuncture (AU)</dc:description>
<dc:creator>Díaz Silva, JJ</dc:creator>
<dc:creator>Sobrido, MJ</dc:creator>
<dc:creator>García Antelo, MJ</dc:creator>
<dc:creator>Santos, H</dc:creator>
<dc:creator>Ivánovic Barbeito, Y</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Se observa un interés creciente por el estudio de los síntomas extranígricos de la enfermedad de Parkinson, como las alteraciones de la marcha, que conllevan una importante disminución de la calidad de vida. La marcha es un proceso complejo cuya afectación puede explicarse por la suma de elementos como hipocinesia, asimetría en el movimiento de ambos hemicuerpos, disfunción ejecutiva, alteraciones en la sensibilidad propioceptiva, factores ambientales y emocionales. En la regulación de la marcha y la postura están implicadas diversas estructuras cerebrales y neurotransmisores que en la enfermedad de Parkinson tienen alterada su activación. En las fases iniciales los trastornos de la marcha son controlados aceptablemente con fármacos dopaminérgicos pero la respuesta a estos medicamentos no es satisfactoria en fases avanzadas, lo cual ha llevado a investigar sustancias con otros mecanismos de acción (metilfenidato, dihidroxifenilserina, anticolinesterásicos, memantina, inhibidores selectivos de los receptores de serotonina, entre otros) y tratamientos no farmacológicos como cirugía (estimulación cerebral profunda del núcleo subtalámico y del pedunculopontino), fisioterapia y acupuntura (AU)</dc:description>
<dc:source>Rev Neurol;54(supl.5): s61-s68, 3 oct., 2012. tab</dc:source>
<dc:identifier>ibc-150366</dc:identifier>
<dc:title xml:lang="es">Tratamiento de los trastornos de la marcha en la enfermedad de Parkinson</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d7148^s22016</dc:subject>
<dc:subject>^d24507^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d24507^s22011</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d10489^s22033</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d33530^s22032</dc:subject>
<dc:subject>^d30331^s22012</dc:subject>
<dc:subject>^d7148^s22032</dc:subject>
<dc:subject>^d10489^s22053</dc:subject>
<dc:subject>^d33530^s22044</dc:subject>
<dc:subject>^d30331^s22016</dc:subject>
<dc:subject>^d12225^s22056</dc:subject>
<dc:subject>^d12225</dc:subject>
<dc:subject>^d32276^s22000</dc:subject>
<dc:subject>^d32181^s22032</dc:subject>
<dc:subject>^d32276^s22055</dc:subject>
<dc:subject>^d32181^s22044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201210</dc:date>
</metadata>
</record>
</ibecs-document>
